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Abstract
Background: One of the most important causes of maternal mortality and severe morbidity worldwide is post 
partum haemorrhage (PPH). Factors as substandard care are frequently reported in the international literature and 
there are similar reports in the Netherlands. The incidence of PPH in the Dutch population is 5% containing 10.000 
women a year. The introduction of an evidence-based guideline on PPH by the Dutch society of Obstetrics and 
Gynaecology (NVOG) and the initiation of the MOET course (Managing Obstetrics Emergencies and Trauma) did 
not lead to a reduction of PPH. This implies the possibility of an incomplete implementation of both the NVOG 
guideline and MOET-instructions. Therefore, the aim of this study is to develop and test a tailored strategy to 
implement both the NVOG guideline and MOET-instructions
Methods/Design: One step in the development procedure is to evaluate the implementation of the guideline and 
MOET-instructions in the current care. Therefore measurement of the actual care will be performed in a 
representative sample of 20 hospitals. This will be done by prospective observation of the third stage of labour of 
320 women with a high risk of PPH using quality indicators extracted from the NVOG guideline and MOET 
instructions. In the next step barriers and facilitators for guideline adherence will be analyzed by performance of 
semi structured interviews with 30 professionals and 10 patients, followed by a questionnaire study among all 
Dutch gynaecologists and midwives to quantify the barriers mentioned. Based on the outcomes, a tailored strategy 
to implement the NVOG guideline and MOET-instructions will be developed and tested in a feasibility study in 4 
hospitals, including effect-, process- and cost evaluation.
Discussion: This study will provide insight into current Dutch practice, in particular to what extent the PPH 
guidelines of the NVOG and the MOET-instructions have been implemented in the actual care, and into the 
barriers and facilitators regarding guideline adherence. The knowledge of the feasibility study regarding the effects 
and costs of the tailored strategy and the experiences of the users can be used in countries with a relatively high 
incidence of PPH.
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Background
The major cause of maternal death worldwide is post par­
tum  haemorrhage (PPH, blood loss of >1000 cc during 
and after delivery), with about 146.000 deaths annually [1]. 
Although this is largely due to deaths in developing coun­
tries, even in the Netherlands it is still in the top four of 
maternal deaths [2]. In this country the reported incidence 
of PPH is 5% in the secondary care, affecting about 10.000 
women annually [3]. In the Lemmon trial (2004-2006), in 
which a large part of Dutch hospitals participated, all 
severe maternal morbidity was documented and PPH in 
absolute number is the major factor contributing to severe 
maternal morbidity [4]. Causes such as substandard care 
are frequently reported in the international literature. In a 
study in France, suboptimal care factors were found in 
38% of women with PPH > 1500 cc and in 70% of women 
who died of PPH. In audits, performed in PPH cases of 
the Lemmon trial, suboptimal care factors were also com­
mon in the Dutch population (unpublished data). A logical 
assumption is that these factors can be overcome by the 
use of evidence based guidelines. The Dutch Society of 
Obstetrics and Gynaecology (NVOG) developed and disse­
minated an evidence-based guideline about PPH, in which 
the best scientific evidence is summarized [5]. Further­
more, in 2003 the MOET course (Managing Obstetric 
Emergencies and Trauma), an ATLS-based course of the 
RCOG, translated to the Dutch situation, was introduced, 
in which stepwise and practical instructions to prevent 
PPH were given [6]. However, without tailor-made imple­
mentation, in general large gaps exist between best evi­
dence as described in guidelines and daily practice [7,8]. 
This also applies to PPH. Both the dissemination of the 
evidence-based guideline about PPH and the MOET 
course did not lead to a reduction in PPH: nationwide the 
incidence of PPH was 3.8% in 2003 and 5.2% in 2006 [3]. 
An incomplete implementation of both the NVOG-guide- 
line and the MOET-instructions is expected.
Methods/Design
Objectives
The first objective of th is study is to asses to what 
extent the NVOG guidelines and the M O ET-instruc- 
tions have been im plem ented in curren t care in the 
Dutch practice. The second objective is to study bar­
riers and facilitators for guideline adherence. Finally 
based on these findings a ta ilo red  im p lem entation  
strategy will be developed and tested on effects, experi­
ences and costs.
Design and study population described per step 
Objective 1
To assess the actual care of Dutch gynaecologists and 
midwives for patients at high risk for PPH (actual care 
study).
Design
Developing quality indicators
Before actual care can be measured, quality indicators 
have to be developed regarding the process, structure 
and outcome of care. These indicators have to be based 
on the key recommendations from the NVOG guideline 
on PPH and the M O E T-instructions. The indicator 
development will be performed according to the RAND- 
modified Delphi method [9]. First the key recommenda­
tions from  the NVOG guideline on PPH and the 
MOET-instructions will be extracted and relevant indi­
cators from international literature will be added. Subse­
quently, the relevance of all these key recommendations 
will be tested in two rounds among an independent 
panel about 15 experts consisting of guideline writers, 
Dutch MOET board members and instructors, NVOG- 
m em bers of the subcom m ittee Im plem entation  and 
Quality, gynaecologists, haematologist and anaesthesiol- 
ogist. In the first round the gathered recommendations 
will be edited in a written questionnaires for the expert 
panel where the experts are asked to score the key- 
recom m endations on a 9-po in t Likert scale ranging 
from 1 = not relevant to 9 = extremely relevant, with 
respect to their impact on both 'health gain' and 'overall 
efficacy. In addition, a top-5 ranking of recom m enda­
tions is asked in which they consider 'm ost im portant' 
and 'representative' to assess the quality of clinical per­
formance. In this round the experts have the possibility 
to provide comments and add additional items as well. 
Of the returned questionnaires, the median scores on 
'health  gain' and 'overall efficacy' are calculated per 
recommendation and are rated valid if they match the 
criteria described by Campbell [10]. Secondly, based on 
the top-5 ranking of recommendations, a list with scores 
reflecting the w eight th a t experts assigned to each 
recommendation will be created. In a second round, in 
a consensus meeting with all the experts these listings 
will be used as feedback. During this meeting this feed­
back will be discussed and the former rankings will be 
reconsidered with the aim to reach consensus about the 
most im portant recommendations to assess the quality 
of clinical performance regarding the adherence to the 
NVOG guideline on PPH and the MOET-instructions. 
The selected key recommendations will be operationa­
lized in measurable elements.
The practical measurement of actual care 
In an observational multi-centre study, actual care will 
be m easured by video m onitoring the th ird  stage of 
delivery and a medical record search among 320 high 
risk patients for PPH in 20 hospitals. In all participating 
clinics, all delivery rooms will be set up with a digital 
camera. In order to avoid anxiety, bias or refusal of par­
ticipation among the care-givers, it is made clear that 
none of the direct colleagues or patients will be able to
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see the images and that these images cannot be claimed 
by the patien t in case of an adverse outcom e. The 
images will be analyzed by the researcher and in a ran­
dom selected subset by one of the project leaders to 
assess the extent of adherence to the developed quality 
indicators. Additional information for indicator adher­
ence will be searched in the m edical records of the 
videotaped patients. In this manner, deviations from the 
indicators can be outlined. This study will provide us 
with reliable information about current practice in the 
Netherlands.
Study population 
Hospitals
In order to obtain a representative view on the actual 
care in the Netherlands, 20 hospitals of different regions 
will participate in this trial including 4 academical, 8 
non academical teaching and 8 non academ ical-non 
teaching hospitals. The study is set in a Dutch Perinatal 
Research Consortium , in which all the participating 
clinics collaborate.
Patients
All patients 18 years and older with a higher risk for 
PPH who will deliver in one of the participating hospi­
tals can be included (16 patients per hospital). This will 
include women with PPH in a previous delivery, m ulti­
ple pregnancy, polyhydram nion, chorio-am nionitis, 
uterus myomatosus, grande multiparity, long delivery, 
clotting disorders or thrombocytopenia (HELLP). Since 
asking permission during the delivery is difficult and the 
higher risk of PPH can develop during delivery, all 
women who visit the antenatal clinic will be asked in 
advance by research nurses to participate. Informed con­
sent will be asked for filming the third stage of labour 
and for reviewing these images by a th ird  party; the 
researcher. The group who declines will be asked per­
m ission to  study their m edical record. In th is way, 
besides the total incidence of PPH in the study period, 
the incidence of PPH in women who participate and 
those who do not participate can be recorded 
Objective 2
To detect barriers and facilitators amongst professionals 
involved in the implementation of the NVOG-guideline 
on PPH and the MOET-instructions and patients (bar­
riers and facilitators study).
Design
A qualitative study will be performed with the aim to 
discover factors in detail th a t are "pro" or "con tra” 
adhering to the developed PPH-indicators. This will be 
performed by focus group interviews among groups of 
different involved professionals (gynaecologists, m id­
wives and gynaecologists in training) and experienced 
patients. The interviewer will explore the following cate­
gories of influencing factors: features of the guidelines 
itself; features of the target group of professionals who
should use the recom m endations; features of patients 
who have to accept or contribute to using the recom ­
mendations; features of the social setting and social net­
work (e.g. colleagues of the involved professionals); 
features of the organizational, economic, and adminis­
trative context. Subsequently, to assess the 'prevalence' 
of the factors mentioned in the focus group interviews, 
a survey with questionnaires will be performed among 
all Dutch gynaecologists and midwives. They will receive 
a web-based questionnaire by e-mail. The data will be 
gathered in an electronic database.
Study population
To select the members of the focus groups, we will con­
tact the national professional associations of respectively 
gynaecologists and midwives and request nominations 
for opinion leaders and the professionals participating in 
the actual care study. The different focus groups will 
consist of respectively 10 gynaecologists, 10 midwives,
10 gynaecologists in training and 10 patients. To select 
the participants for the survey with questionnaires, we 
will contact the national professional associations of 
respectively gynaecologists and midwives and request e­
mail addresses.
Objective 3
Development and testing an implementation strategy in 
terms of effectiveness, experiences of participants, pro­
cess and costs. (feasibility study):
Design
Based on the results of step 1 and 2, a tailored imple­
m entation strategy will be developed to increase the 
adherence to the recom m endations. Because different 
barriers at different levels are expected, it is very likely 
that a strategy with different implementation elements 
directed at both professional and organizational level 
will be developed. A t th is m om ent, we have some 
hypotheses about expecting limitations in actual care. At 
the level of the guideline/M OET-instructions itself we 
th ink th a t the guideline can be m ore specific; the 
description of the desired care is not detailed enough. 
The desired care can be described in a detailed and 
s truc tu ra l m anor by the developm ent of "bundles”. 
These bundles are defined as a group of interventions 
related  to a disease process that, when executed 
together, results in better outcome than when im ple­
m ented individually. A second lim itation could be a 
delayed time interval between events and taken actions, 
(right actions taken too slowly due to individual deci­
sions or organizational factors). The solution could also 
be describing the desired care in bundles in the guide­
line and on organizational level an improvement process 
can be undertaken if the exact problem can be identified 
for example; multidisciplinary clear agreements. At the 
level of the professionals, a lack of knowledge/insight in 
own perform ance can be an im pending factor. The
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installed monitors could be used to constant audit and 
feedback their perform ance, bo th  individual and in 
review conferences and team training could be an inter­
vention. However, due to uncertainty of existing barriers 
and facilitators the strategy can not be worked out in 
detail now.
Intervention
The tailored improvement strategy will be implemented 
and evaluated in a feasibility study in nine months. The 
study will be performed in 4 hospitals (also participating 
in the actual care study) and consists of three 
evaluations:
a) To obtain an indication of the effect of the imple­
mentation strategy, the adherence to the developed indi­
cators will be measured before (= actual care study) and 
after the introduction of the newly developed strategy, 
using videotaping and a medical record search (see step 
1b). For the after-m easurem ent we will include about 
100 patients.
b) A process evaluation will be performed to study the 
experiences of the clinicians and patients with the chan­
ged care and also to study the extent by which clinicians 
and eventually patients use the elements of the strate­
gies and their experiences (e.g. satisfaction and feasibil­
ity) w ith these elem ents. To achieve this, process 
information will be gathered in a qualitative study in the
4 participating hospitals and individual interviews will 
take place among the different involved gynaecologists, 
midwives and patients.
c) A cost analysis of the tested implementation strat­
egy will take place. The perspective of this analysis will 
be the health care perspective. The costs of the imple­
m entation  strategy will be estim ated by an Activity 
Based Costing approach focusing on activities performed 
to im plem ent the NVOG-guideline on PPH and the 
MOET-instructions, with the costs accumulated at the 
activity level(s) of the health care implementation pro­
cesses. The costs of im plem entation of the guidelines 
and consolidation consist of personnel and m aterial 
costs. The input of resources will be assessed by collect­
ing volumes of consum ed resources and multiplying 
these by the price of each resource unit. The prices of 
each resource unit will be based on standard costs, mar­
ket prices or self-determined costs [11]. In the analysis, 
the im plem entation costs will be related to the differ­
ence in percentage of patients treated according to the 
guideline indicators in the situation before and after the 
im plem entation of the NVOG-guideline on PPH and 
the MOET-instructions
Study population
To study the feasibility, four hospitals and their respec­
tive gynaecologists and midwives will participate in two 
different regions in the Netherlands. In each region, an 
academic hospital and a non-academ ic hospital will
participate. The inclusion criteria and course of manage­
ment for the 100 patients in the 'after-measurement' will 
be the same as in the actual care study. For the process 
evaluation all gynaecologists and midwives of the 
included patients are asked to participate.
Outcome measures 
Actual care study
The primary outcome measure is the adherence to the 
quality indicators (derived from the NVOG guideline on 
PPH and the MOET-instructions). The secondary out­
come measure is outcome of care (e.g. the incidence of 
PPH).
Barrier and facilitator study
The main outcome is the different types and frequency 
of found barriers and facilitators for implementation of 
the NVOG guideline and MOET-instructions regarding 
gynaecologists, midwifes and patients.
Feasibility study
To get an indication of the effectiveness of the strategy 
the primary outcome measure is the adherence to devel­
oped quality indicators. O ther outcome m easures are 
the experiences of the participants (both professionals 
and patients) with the elements of the strategy and with 
the changed care. Also the cost of the tested strategy 
will be measured.
Statistical issues
Sample size calculation actual care study and feasibility of 
recruitment
Assuming accordance with the guidelines of 50%, with an 
alpha of 0.05, a precision of the estimation of 0.075, 171 
patients have to be included. However, taking clustering of 
data within clinicians into account, this number has to be 
multiplied by the design effect. W ith 5 patients per clini­
cian and an intraclustercorrelation of 0.20 this effect is 1.8. 
So the m inim um  num ber of patients that have to be 
included is 1.8 x 171 = 308 patients. In order to compen­
sate for lost to follow-up or incomplete data, 320 women 
have to be included in 20 hospitals in 6-9 months.
Data analysis
Analysis of the actual care study
To analyse actual care, frequencies of adherence per 
quality indicator will be calculated. Furtherm ore, the 
variation in this care between the different hospitals will 
be calculated.
Analysis of the barriers and facilitators
The barriers and facilitators m entioned in the focus 
group interviews with professionals and patients will be 
qualitatively analysed, using the qualitative software 
package (Atlas). In the quantification of these barriers, 
frequencies of found barriers and facilitators will be 
calculated.
Analysis of the feasibility study
In the effectuation the proportion of patients that are 
treated in accordance with the guidelines (analysed on
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the basis of the indicator set) before and after im ple­
m entation of the guidelines will be established. Both 
univariate and m ultivariate (multi-level) analyses are 
performed to demonstrate the effect of the implementa­
tion strategy in increasing the proportion of patients 
who are treated according to the guidelines. In addition, 
for the process evaluation, frequencies are used to asses 
the experiences of the professionals and patients to the 
im plem entation programme elements. Analyses of the 
costs of the implementation strategy will be conducted 
by multiplying the volumes of consumed resources with 
the price of each resource unit.
Ethical considerations
The study protocol has been presented to the Medical 
Ethical Committee (CMO) of the region Arnhem  and 
Nijmegen (ABR no. NL25975.091.08). Ethical approval 
was no t necessary. The protocol is registered in the 
ClinicalTrials.gov register (NCT00928863)
Discussion
This study addresses an im portan t problem  because 
PPH is currently the m ajor cause of severe m aternal 
m orbidity in the Netherlands. Many different factors 
determine the action that is taken in case of more than 
average blood loss or once a real PPH sets in. Insight 
in to these factors is of great im portance in order to 
know what kind of activities should be developed to pre­
vent PPH by im plem enting the NVOG-guideline and 
MOET-instructions. In literature, the following facilita­
tors and barriers are distinguished: features of the inno­
vations itself, of the target group of professionals who 
should use the innovation, of patien ts who have to 
accept or contribute to the innovation, of the social set­
ting and network and of the organisational, economic 
and administrative context [12]. To our knowledge the 
proposed study is the first study on barriers and the 
development and testing of a tailored im plem entation 
strategy for acute care situations in the obstetrics. A 
randomized controlled study is the next step to measure 
the effectiveness of the implementation of the obtained 
strategy if the result of this study is that the strategy is 
feasible in practice, can be implemented with low costs 
and indicates to be effective. Ultimately, the generated 
knowledge and understanding of the im plem entation 
process can be used to implement guidelines in different 
countries with similar problems and hopefully lead to a 
worldwide reduction of the incidence of PPH
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